What is Hinge Bio?
Hinge Bio is a pioneering biotechnology firm dedicated to redefining antibody-based therapeutics through its proprietary GEM-DIMER platform. By engineering molecules with unprecedented degrees of multivalency and multispecificity, the company seeks to address complex disease states with superior safety and efficacy profiles. This innovative approach represents a significant departure from traditional therapeutic modalities, positioning Hinge Bio as a high-growth entity within the competitive life sciences sector.
The company is currently managed by a seasoned leadership team with a proven track record in drug development. Their focus remains on translating preclinical data into tangible clinical outcomes, effectively bridging the gap between laboratory innovation and patient-centric healthcare solutions.
How much funding has Hinge Bio raised?
Hinge Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2025): $30M with participation from Point72, InVivium Capital, Lightswitch Capital, and Ridgeback Capital
Key Investors in Hinge Bio
Point72
A prominent private investment management firm with a diverse portfolio, specializing in long-short equity and quantitative strategies.
InVivium Capital
A venture capital fund focused on transformative life sciences and healthcare innovations that drive meaningful change in patient care.
Lightswitch Capital
An investment firm dedicated to empowering private healthcare companies through long-term growth capital and strategic operational support.
What's next for Hinge Bio?
Looking ahead, Hinge Bio is poised to utilize this capital to scale its GEM-DIMER programs and expand its internal capabilities. The strategic roadmap includes the continued presentation of preclinical data to validate the platform's efficacy, alongside the recruitment of top-tier talent to bolster its senior management team. As the company moves closer to clinical development, the focus will shift toward regulatory milestones and potential partnerships that could further validate its technological platform. The infusion of resources ensures that Hinge Bio remains at the forefront of next-generation therapeutic development, providing the necessary runway to navigate the complexities of the modern healthcare market.
See full Hinge Bio company page
